Companies are requesting emergency approval of drug for the early treatment of COVID-19
News
Novartis UK signs digital partnership with Cievert for chronic disease management
Initiative is aiming to support NHS patient care in rheumatology and dermatology
Five new meds recommended in March CHMP decisions
The committee also recommended six extensions of current therapeutic indications
Researchers identify new genetic clues for ‘silent’ strokes
British Heart Foundation-funded researchers hope findings can aid the development of new treatments
Cancer Research UK launches new ‘cancer tech accelerator’ programme
New initiative aims to help researchers translate their ideas into innovations for cancer patients
EMA accepts Astellas/Seagen’s enfortumab vedotin for review
Marketing authorisation application is seeking approval for advanced urothelial cancer
NHS England makes Keytruda available for advanced colorectal cancer during pandemic
Interim treatment agreement reached for eligible patients during COVID-19 pandemic
Relugolix shows potential long-term benefit in women with uterine fibroids
Study compared women who continued on relugolix combination therapy with women who discontinued treatment
Cambridge start-up PhoreMost raises £33m to progress PLK1 programme
Lead ‘Allosteric PLK1’ asset will initially target brain cancer
UK Health Security Agency launches to address ‘future health threats’
New national agency will plan for, prevent and respond to external health threats including infectious diseases
AstraZeneca’s updated COVID-19 vaccine trial results show 76% efficacy
Initial results from US trial published earlier this week said the vaccine was 79% effective
Report urges pharma companies to utilise synthetic data in clinical trials
Report outlines two cases for using synthetic data in the clinical trial process
Zealand Pharma’s hypoglycaemia therapy Zegalogue scores approval in the US
Therapy authorised for the treatment of severe hypoglycaemia in people with diabetes
AZ to issue primary analysis for COVID-19 vaccine following ‘outdated information’ concerns
US data and safety monitoring board expressed ‘concern’ over initial trial data
FDA refuses Novo Nordisk’s once-weekly semaglutide
Company had been aiming for approval in type 2 diabetes
